Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids

Inclusion Criteria

• •HCT recipients over 12 years of age within the first 7 days of initial treatment of high-risk aGVHD, defined as:
• •Newly diagnosed Minnesota high-risk aGVHD -OR-
• •Newly diagnosed Minnesota standard risk aGVHD with plasma amphiregulin ≥ 33 pg/ml tested at the UMN Cytokine Reference Lab. For amphiregulin lab ordering information, see Fairview Lab Guide: http://labguide.fairview.org/showtest.asp?testid=6766\&format=long -OR-
• •Newly diagnosed Minnesota standard risk aGVHD Ann Arbor 3 biomarkers tested by Viracor. For ordering information, see: https://www.viracor-eurofins.com/test-menu/403572p-agvhd-symptomatic- onset-algorithm/
• •* Renal: Serum creatinine ≤2.5x upper limit of normal (ULN)
• •* Cardiac: Left ventricular ejection fraction (LVEF) ≥ 35%
• •* Voluntary written consent (adult or parent/guardian with minor assent for 12 through 17-year-olds).